A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

NCT06039449 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

790

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
SARS-CoV-2

Interventions

DRUG: VYD222 (pemivibart)
DRUG: Normal saline

Sponsor

Invivyd, Inc.